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It is accepted that cancer results from the accumulation of mutations in genes 
controlling cell birth or cell death. Also, the microenvironment, including stromal and 
vascular endothelial cells, is important for the growth and persistence of the cancer 
cell. This entire constellation of the abnormal molecular biology of cancer cells and 
their microenvironment is the signature of cancer. However, we still do not 
understand the mechanisms leading to the origin of cancer cells sufficiently well to 
have an impact on cancer mortality. The most critical point of cancer development is 
the transition from a normal target cell to a cancer cell. However, the mechanisms 
establishing tumor cellular identity, which play an essential role in allowing cancers to 
arise, have received little attention. Recently, it has been hypothesized that cancer 
cells are cellular states arising as a result of external perturbations, implying that 
mutation would not be a direct cause for cancer origin, and that generation of 
cancercells would be strongly dependent on cell-cell interactions and environmental 
variation. From this perspective, there are three key questions for understanding the 
cancer initiation process. What are the cues instructing a target cell to switch from a 
normal to a cancerous fate? What is the molecular nature of the cancer cell switch?  
When, during normal cell development, does this switch take place? This last question 
is critical because, to find the players of the normal/cancer switch mechanism, one has 
to know when/ where to look. The mechanisms initiating cancer must integrate 
developmental cues (different between cancer types) with the universal requirements 
for the creation of a tumor mass. Although it is generally believed that the decision to 
become a cancer cell must be made once the normal cell has adopted a cell fate 
compromise in the majority of cancers, recent data suggest that this timing of cancer 
initiation is not a universal feature shared by many oncogenes. Actually, several recent 
papers have found that oncogenes contribute to cancer development not only by 
inducing proliferation, but mainly via developmental reprogramming of the 
epigenome. Indeed, using stem-cell restricted transgenic expression systems, it has 
been shown that the expression of the oncogene in the reprogramming-prone 
stem/progenitor cells is capable of programming the development of all the cells that 
compose the tumor mass. Overall, these results not only highlight a previously 
unrecognized role for oncogenes in cancer, but also provide evidence for a previously 
unmodeled process for tumorigenesis in which the programming of the malignant 
phenotype has already taken place at the stem cell stage, thus uncovering a new role 
for oncogenes in the timing of cancer initiation. In this context, mutations that activate 
oncogenes would have a driving role in the reprogramming process, but may act as 
passenger mutations (or have a secondary, different role) thereafter. These findings 
lead to new questions. First, is the decision to initiate cancer made at one time point 
during the differentiation process, or are a series of consecutive decisions required to 
switch to a cancer-cell fate? and, are all these decisions cell-autonomous? What is the 
nature of the (epi)genetic pathway downstream from the cancerspecific initiation gene 
defect(s)? If we learn how to stop cancer development by manipulating the cancer-
initiation program then, someday, understanding the initiation of cancer will also be 
useful for cancer therapy. 
